



Fluart Innovative Vaccines

Innovating the future
of **biotechnology**

Company brochure 2025





We believe that our modern scientific efforts and advanced manufacturing processes have the power to fundamentally transform medicine - making the once impossible possible for millions.

Our work is grounded in research, development, and innovation, with a strong focus on tackling healthcare challenges where our proven expertise can deliver meaningful, positive outcomes.





COMPANY BROCHURE

About us

Fluart Innovative Vaccines Ltd. is Hungary's only pharmaceutical, biotechnology, and life science research company that has been a pioneer in the research, development, and production of influenza vaccines since 1991.

We are dedicated to health innovation and play a key role in ensuring broad access to **influenza vaccines**. With decades of experience in human vaccine manufacturing and research, we support the (bio)pharmaceutical and medical device industries through our **laboratory, manufacturing, and consulting services**.

Our **GMP-approved** and accredited laboratories offer a wide range of analytical and testing methods to meet diverse industry needs.



34+
years of experience



50+
scientific, professional
collaboration



35+
million vaccines produced



1800+
square meters of R&D and
manufacturing infrastructure



10+
scientific publication



90+
full-time employees

About us

Our services are comprehensive, covering active pharmaceutical ingredients, finished products, intermediates, biologicals, and pharmaceutical raw materials. We support our customers in developing test methods from the ground up or transferring existing methods under fully compliant regulatory conditions.

In addition to analytical testing, we offer aseptic manufacturing facilities for small-scale production, including fill and finish operations and packaging services

- ensuring end-to-end support across the product lifecycle.

Beyond our vaccine activities, we are actively engaged in research and development across several innovative fields focused on treating viral and bacterial pathogens. A key priority among these is the fight against nosocomial infections.

Our Research & Development projects deliver solutions across multiple critical sectors, including pharmaceuticals, biotechnology, food, and animal health.





Fluart in Hungary

Building on more than **34 years** of pharmaceutical manufacturing tradition in Hungary, Fluart is a biotechnology company with a strong presence, operating two manufacturing plants across five sites.

We employ over **90** professionals across pharmaceutical manufacturing, commerce, research and development, contract manufacturing and development, and business services.

Our rapidly growing centers in Pilisborosjenő and Debrecen drive several key initiatives, including new product development, technological innovation, and the **formation of international partnerships**.

Our goal is to strengthen our market position further and contribute to the advancement of healthcare both in Hungary and worldwide.

1991

Start-Up Phase & Expansion

We began producing influenza vaccines, laying the foundation for our future growth and expertise in vaccine manufacturing.

2006

New Business Lines

We expanded into technology transfer, research, and development, broadening our capabilities and scope within the biotechnology industry.

2023

Fluart Entry as a CDMO

We embraced new challenges as a CDMO, offering comprehensive services from early-phase development to commercial production.





Pharmaceutical manufacturing and R&D developments




PILISBOROSJENŐ SITE

The primary focus of our Pilisborosjenő site is the manufacturing, packaging, and research and development of vaccines. We produce the 3Fluart® seasonal influenza vaccine, a recognized medicinal healthcare product. As we celebrate the 30th anniversary of our site, we remain committed to investing in projects that drive innovation now and into the future. Our facility supplies the Hungarian market with our products, and our team of over 60 dedicated employees delivers up 1.6 million ampoules of vaccine to patients each year.

R&D DEVELOPMENTS

We are focused on research and development, with a special interest in combating serious human and animal infections through the application of bacteriophage therapy. We are seeking national and international collaborations to ensure that the discoveries and innovations established by our experts have a meaningful impact on the global market. Our goal is to deliver innovative solutions that address health and agricultural challenges worldwide, supporting sustainable development and advancing public health. We are committed to translating scientific breakthroughs into real-world applications that improve lives and ecosystems.





Business unit activities

Whether in business services or vaccine production, our employees consistently deliver innovative, high-quality work across all professional areas - meeting both national and international standards. We are a key player in the Hungarian vaccine market, with particular strength in the research, development, and production of influenza vaccines.

Through our CDMO services, we offer dependable support from clinical trials to full-scale commercial manufacturing. Our R&D efforts also extend to bacteriophage research, animal health, and the food industry. All production is conducted in compliance with GMP regulations, ensuring smooth and reliable scale-up.





BUSINESS UNITS

Influenza vaccines

We are a leading and active player in the Hungarian vaccine market, excelling in the research, development, and aseptic production of both pandemic and seasonal influenza vaccines. Our high-quality products provide effective protection and are based on proprietary formulations containing inactivated, adjuvanted whole virus. Our vaccines consistently meet the quality, efficacy, and safety standards required by both national and international regulations.

To date, we have produced and distributed over 35 million doses of our 3Fluart® seasonal and 1Fluart® pandemic influenza vaccines. We place strong emphasis on combating influenza, contributing to the prevention and protection of millions of people across Hungary every year.

3Fluart® seasonal influenza vaccine (whole virus, inactivated, adjuvanted) is a reduced-active-substance vaccine containing 6 µg haemagglutinin (HA) per strain of the seasonal influenza epidemic virus strains A/H1N1, A/H3N2, B/Victoria, which is in line with the current influenza seasonal recommendations of the World Health Organization (WHO) and the European Medicines Agency (EMA).



1Fluart® pandemic influenza vaccine (whole virus, inactivated, adjuvanted), containing 6 µg haemagglutinin (HA)/strain. The vaccine contains the pandemic strain of the virus and is formulated in accordance with the recommendations of the World Health Organization (WHO) and the European Medicines Agency (EMA) for the current pandemic situation.





BUSINESS UNITS

CDMO services

Fluart Innovative Vaccines provides comprehensive contract development and manufacturing services across all stages of drug development. As your trusted partner in GMP contract manufacturing, we offer a complete, in-house service portfolio to meet your pharmaceutical manufacturing needs.

Our one-stop-shop approach ensures seamless execution - from sourcing and blending to aseptic filling, finishing, release, and GDP-compliant distribution. With all services under one roof, we deliver reliable, high-quality solutions tailored to your pharmaceutical project.

Why choose Fluart Innovative Vaccines for your contract manufacturing needs?

- **High Flexibility:** Our focus on small-scale projects enables a high degree of flexibility in both our services and your fill & finish processes.
- **QP Release:** We offer internal Qualified Person (QP) release capabilities to ensure smooth and timely product certification.
- **Efficiency:** Our proactive, solution-oriented project managers ensure efficient communication and streamlined execution throughout every phase of your project.
- **Comprehensive GMP Services:** Our full GMP contract manufacturing portfolio is supported by our certified laboratories, approved by NNGYK, offering additional analytical, manufacturing, and support services as needed.





BUSINESS UNITS

Research and development

Fluart's R&D efforts reflect our long-standing commitment to advancing solutions against influenza and other serious human and animal infections.

Our scientists are actively developing novel and innovative treatments, positioning us at the forefront of next-generation vaccine research. Beyond vaccines, our development projects and service portfolio address the needs of various industrial sectors, including bacteriophage research, animal health, and the food industry.

We are currently engaged in cutting-edge vaccine research, including virus vector and subunit platforms, while continuing to expand our capabilities across a diverse range of biomedical and industrial fields.

Our pipeline

Areas of scientific focus

- 1** Bacteriophage formulation / therapy use
- 2** SARS-COV2 technology
- 3** Viral subunit vaccine development





BUSINESS UNITS

Technology transfer

Our technology transfer programme is available globally, serving as a vital bridge to close R&D gaps, enhance vaccine availability, and stimulate investment in key industrial sectors.

This initiative aims to boost the self-sufficiency of low-income countries by enabling them to develop national capacities to address seasonal and pandemic influenza challenges. It accelerates the acquisition of knowledge, expertise, and equipment necessary for advanced, innovative industrial products and processes.

Vaccine-related technology transfer also delivers unique benefits - advancing global health and fostering sustainable economic development within the broader innovation ecosystem.



Responsible employer

We are dedicated to providing our employees with a stable, safe, and high-quality workplace within a stimulating, modern office environment equipped with advanced industrial technologies - making every workday motivating and rewarding.

We actively promote work-life balance through tailored company programs and both external and internal training opportunities. Flexible work arrangements, including part-time roles, adjustable schedules, and work-from-home options, support these commitments.

Distribution by headcount and gender

90+

total number of employees

63%

women in the organisation

37%

man in the organisation



Our corporate responsibility

Fluart is committed to sustainability, leveraging heat pump technology and solar energy to reduce carbon emissions and optimize energy efficiency.

In recent years, we have cut our water consumption by 42% through the recycling of process water, further enhancing our resource efficiency.

We prioritize continuous training to foster our staff's professional growth and maintain modern working conditions. Our dedication extends to the sustainable production of influenza vaccines and active participation in social awareness campaigns.

Supporting the local community is a core value for us. We create jobs, back local events, and contribute to regional economic stability. Additionally, we support scientific conferences and professional initiatives across the country.





**WE ARE LEADING
HEALTHCARE INNOVATION.**

**For business or
collaboration,
contact us.**

 www.fluart.hu

 sales@fluart.hu

